Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models

Copanlisib is a pan–class I phosphoinositide 3-kinase (PI3K) inhibitor with preferred activity toward PI3Kα and PI3Kδ. Despite the clear overall clinical benefit, the number of patients achieving complete remissions with the single agent is relatively low, a problem shared by the vast majority of ta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Tarantelli, Chiara, Lange, Martin, Gaudio, Eugenio, Cascione, Luciano, Spriano, Filippo, Kwee, Ivo, Arribas, Alberto J., Rinaldi, Andrea, Jourdan, Thibaud, Berthold, Melanie, Sturz, Andrea, Sperl, Carolyn, Margheriti, Francesco, Scalise, Lorenzo, Gritti, Giuseppe, Rossi, Davide, Stathis, Anastasios, Liu, Ningshu, Zucca, Emanuele, Politz, Oliver, Bertoni, Francesco
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2020
Schlagworte:
Lymphoid Neoplasia
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065481/
https://ncbi.nlm.nih.gov/pubmed/32126142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000844
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge